GH — Guardant Health, Inc.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1576280 ·
Last close
$177.33
Market Cap
$23.80B
52W High
$183.51
52W Low
$59.63
ADV30
1,958,724
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 334,978,000 | 219,029,000 | -129,118,000 | -120,142,000 | 1,912,294,000 | 1,053,469,000 | 2,135,161,000 |
| Mar 2026 | 301,665,000 | 196,746,000 | -121,350,000 | -112,075,000 | 1,915,291,000 | 989,291,000 | 2,096,364,000 |
| Dec 2025 | 281,266,000 | 181,774,000 | -120,805,000 | -128,494,000 | 2,013,659,000 | 378,203,000 | 2,112,966,000 |
| Sep 2025 | 265,196,000 | 171,609,000 | -98,989,000 | -92,725,000 | 1,276,786,000 | 580,013,000 | 1,631,259,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-185,187,000
Investing CF
$-118,526,000
Financing CF
$737,796,000
CapEx
$-55,537,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-3.49
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,226,729,000
Inventory
$105,463,000
Receivables
$144,249,000
ST Investments
$0
EBIT TTM
$-449,654,000
Pretax Income TTM
$-454,470,000
Interest Exp TTM
$4,816,000
Analysts
24
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,183,105,024
EBITDA
$-430,571,008
Free Cash Flow
$26,607,000
Enterprise Value
$21,763,338,240
Total Cash
$1,053,468,992
Total Debt
$1,697,012,992
Shares Out
134,196,170
Trailing EPS
$-3.51
Book Value
$-1.67
ROE
—
ROA
-18.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 982,021,000 | -437,248,000 | -416,277,000 | 2,013,659,000 | 2,112,966,000 | -99,307,000 | -184,760,000 |
| Dec 2024 | 739,016,000 | -443,594,000 | -436,373,000 | 1,485,609,000 | 1,625,256,000 | -139,647,000 | -239,858,000 |
| Dec 2023 | 563,948,000 | -564,725,000 | -479,449,000 | 1,786,421,000 | 1,627,737,000 | 158,684,000 | -324,975,000 |
| Dec 2022 | 449,538,000 | -544,378,000 | -654,588,000 | 1,609,985,000 | 1,549,805,000 | 60,180,000 | -309,463,000 |
TTM Snapshot
Revenues TTM
$655,381,000
NetIncome TTM
$-451,009,000
OpCashFlow TTM
$0
Assets (Latest)
$2,013,659,000
Forward EPS
$-0.40
Max Pain — expiry 2026-10-16
max pain strike: $160.00 · spot: $177.33 · call oi: 5,826 · put oi: 4,329
Expected Move to 2026-10-16:
±$15.55
(8.77%) —
implied range
$161.78 –
$192.88
· ATM straddle on $175.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LH | LABCORP HOLDINGS INC. | $25.11B | $309.57 | — |
| DGX | QUEST DIAGNOSTICS INC | $26.23B | $237.62 | — |
| THC | TENET HEALTHCARE CORP | $20.77B | $257.93 | — |
| EHC | Encompass Health Corp | $12.23B | $124.02 | — |
| FMS | Fresenius Medical Care AG | $12.21B | $22.95 | — |
News headlines (Yahoo Finance, 1h cache)
FDA Advisors Said It Should Approve the Grail Multicancer Blood Test. The Stock Rises Sharply.
2026-09-24 14:52 · Yahoo
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.
2026-09-21 20:00 · Yahoo
Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role
2026-09-18 05:14 · Yahoo
Guardant Health Nears Buy Point As Sales Outlook Brightens
2026-09-16 16:39 · Yahoo
Dow Jones Futures Rise As Oil Prices, Yields Fall Before Fed Rate Hike; Will Market Rally Bid Bond Voyage?
2026-09-16 12:07 · Yahoo
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
2026-09-14 20:05 · Yahoo
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
2026-09-09 19:46 · Yahoo
What Makes Guardant Health (GH) a Compelling Bet?
2026-09-08 13:22 · Yahoo
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection
2026-09-05 00:07 · Yahoo
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
2026-09-04 22:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.